EarningsQ2 2026 Earnings Report

Helus Pharma (HELP) Q2 2026 Earnings Report

2,591 Followers

Previous Report: Q1 2026

Next Report: Q3 2026

HELP Q2 2026 EPS Results

Actual EPS-$1.33

Consensus EPS-$1.02

Beat/MissMissed by -$0.31

One Year Ago EPS-$2.01

HELP Q2 2026 Revenue Results

Actual Revenue$0.00

Expected Revenue$0.00

Beat/MissMet expectations

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ2 2026

Date11/13/2025

TimeBefore Open

Conference CallThursday, November 13, 2025

HELP Upcoming Earnings

Helus Pharma's next earnings date is estimated for November 16, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

HELP Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Nov 13, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call reflects a company making significant progress in advancing its clinical programs and strengthening its financial position, despite facing challenges such as leadership transition and increased expenses. The overall sentiment is balanced, with solid achievements in clinical and operational fronts but offset by financial and leadership concerns.

Company Guidance

In the recent call, Cybin provided several key metrics and updates regarding their ongoing programs and financial status. The company has raised $175 million in recent financing, aiming to advance their lead programs, CYB003 and CYB004, towards significant data readouts. CYB003, a deuterated psilocin analog, is in Phase III for major depressive disorder and has expanded its global footprint, targeting 330 participants across approximately 60 clinical sites. CYB004, targeting generalized anxiety disorder, has completed Phase II enrollment, with top-line data expected in Q1 2026. For the fiscal quarter ending September 30, 2025, Cybin reported cash-based operating expenses of $28.5 million and a net loss of $33.7 million. The company ended the quarter with $83.8 million in cash, cash equivalents, and investments, projecting these funds to support operations into 2027. Cybin emphasizes a disciplined approach to capital deployment, focusing on measurable milestones, global site activations, and manufacturing readiness to ensure successful execution of their clinical and commercial strategies.

Advancement in Clinical Programs

CYB003 Phase III program for major depressive disorder and CYB004 Phase II program for generalized anxiety disorder are progressing as planned. The CYB004 study completed enrollment and is on track for a top line readout in the first calendar quarter of 2026.

Successful Financing and Strengthened Capital Position

Closed a $175 million financing, providing flexibility to execute plans and retire convertible debentures. Ended the quarter with $83.8 million in cash, cash equivalents, and investments.

Global Study Expansion

EMBRACE Phase III study for CYB003 has been cleared to commence in the United States, U.K., multiple European Union countries, and Australia.

Operational and Commercial Readiness

Partnership with Thermo Fisher for manufacturing and Osmind for point-of-care software to enhance clinic workflow and data management.

Positive Market and Investor Confidence

Participation from prominent institutional healthcare investors in recent financing reflects confidence in Cybin's science and programs.

HELP Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 16, 2026	2027 (Q2)	-0.69 / -	-1.333	―
Aug 14, 2026	2027 (Q1)	-0.84 / -0.89	-1.083	18.04% (+0.20)
Jun 29, 2026	2026 (Q4)	-0.80 / -0.93	-1.026	8.90% (+0.09)
Feb 13, 2026	2026 (Q3)	-0.73 / -0.96	-0.372	-157.17% (-0.59)
Nov 13, 2025	2026 (Q2)	-1.02 / -1.33	-2.01	33.71% (+0.68)
Aug 13, 2025	2026 (Q1)	- / -	-0.534	―
Jul 01, 2025	2025 (Q4)	-0.92 / -1.08	-0.534	-102.76% (-0.55)
Feb 11, 2025	2025 (Q3)	-0.74 / -0.37	-2.404	84.50% (+2.03)
Nov 13, 2024	2025 (Q2)	-0.93 / -2.01	-1.335	-50.53% (-0.67)
Aug 08, 2024	2025 (Q1)	-0.93 / -0.53	-1.87	71.43% (+1.34)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed